Ram Sharma, MD
Interventional Cardiology · Smyrna, TNNPI 1447212964
Payments from drug & device makers
Across 294 payments — averaging $60.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Esperion Therapeutics, Inc.$9K
- Cardiovascular Systems Inc.$1K
- Actelion Pharmaceuticals US, Inc.$1K
- AstraZeneca$903
- Asahi Intecc USA, Inc.$756
- Amgen$649
- plus $3K from 33 others
What the payments were for
- Speaking & faculty fees$9,18052%
- Travel & lodging$1,6419%
- Food & beverage$6,57037%
- Education$2922%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Esperion Therapeutics, Inc. | 12 | $9,409 |
| Cardiovascular Systems Inc. | 12 | $1,401 |
| Actelion Pharmaceuticals US, Inc. | 47 | $1,115 |
| AstraZeneca | 39 | $903 |
| Asahi Intecc USA, Inc. | 5 | $756 |
| Amgen | 32 | $649 |
| Johnson & Johnson | 24 | $449 |
| Boston Scientific | 4 | $387 |
| Merck | 15 | $373 |
| Novartis | 24 | $325 |
| Abbott | 7 | $252 |
| Shockwave Medical, Inc | 2 | $223 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 14 | $189 |
| Amarin Pharma, Inc. | 6 | $132 |
| Teleflex LLC | 1 | $130 |
| Novo Nordisk | 2 | $125 |
| Sanofi-aventis U.S. LLC | 7 | $125 |
| Edwards Lifesciences | 8 | $110 |
| Harmony Biosciences LLC | 1 | $85 |
| Lexicon Pharmaceuticals, Inc. | 3 | $69 |
| Cardiva Medical, Inc. | 3 | $61 |
| Regeneron Healthcare Solutions, Inc. | 3 | $54 |
| Lundbeck LLC | 3 | $43 |
| Boehringer Ingelheim | 2 | $41 |
| Pfizer | 2 | $35 |
| Stryker | 1 | $30 |
| E.r. Squibb & Sons, L.L.C. | 2 | $26 |
| Jazz Pharmaceuticals Inc. | 1 | $21 |
| Scpharmaceuticals Inc. | 1 | $20 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $20 |
| Bridgebio Pharma, Inc. | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Terumo Medical Corporation | 1 | $15 |
| Bayer | 1 | $14 |
| Gilead | 1 | $13 |
| Celonova Biosciences, Inc. | 1 | $12 |
| Penumbra, Inc. | 1 | $12 |
| Bardy Diagnostics, Inc. | 2 | $12 |
| Medtronic | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NEXLIZET$9,281
- NEXLETOL$9,281
- Coronary Orbital Atherectomy System$802
- ASAHI PTCA Guide Wire$659
- Peripheral Orbital Atherectomy System$411
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$203
- TRAPLINER$130
- GENERAL - STENTS$122
- GENERAL ULTRASOUND$121
- XARELTO$120
- MitraClip$118
- Repatha$118
- WINREVAIR$117
- UPTRAVI$114
- OPSUMIT$114
- Diamondback Peripheral$106
- Diamondback Coronary$106
How this compares
$17,683 in reported general payments places this provider in the 65th percentile of 207 interventional cardiology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 28 | $348,381 |
| EliquisApixaban | 180 | $163,384 |
| XareltoRivaroxaban | 90 | $111,272 |
| EntrestoSacubitril/Valsartan | 61 | $72,323 |
| FarxigaDapagliflozin Propanediol | 58 | $63,267 |
| BrilintaTicagrelor | 48 | $36,032 |
| Repatha SureclickEvolocumab | 45 | $31,833 |
| Ranolazine ErRanolazine | 159 | $31,238 |
| Valsartan | 212 | $12,286 |
| Amiodarone Hcl | 152 | $9,155 |
| Prasugrel Hcl | 45 | $5,705 |
| Atorvastatin Calcium | 449 | $5,457 |
| Carvedilol | 603 | $4,857 |
| ClopidogrelClopidogrel Bisulfate | 294 | $3,169 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 205 | $2,837 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit | $1,115 | $348,38128 claims |
| PfizerEliquis | $35 | $163,384180 claims |
| Johnson & JohnsonXarelto | $449 | $111,27290 claims |
| AstraZenecaFarxiga, Brilinta | $903 | $99,298106 claims |
| NovartisEntresto | $325 | $72,32361 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 207 interventional cardiology providers in Tennessee.
Other interventional cardiology in Smyrna
- Michael MorseNashville$3.5M
- Charles TreasurePowell$3M
- Colin BarkerNashville$2.1M
- Brian JeffersonNashville$2.1M
- Malcolm FosterKnoxville$1.9M
- Rahul SakhujaKingsport$1.9M
- Kashish GoelNashville$1.1M
- Samuel HorrNashville$912K
- Mehul PatelGermantown$810K
- Jimmy KerriganNashville$769K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.